Literature DB >> 21755323

Cost-effectiveness of biologics compared with disease-modifying antirheumatic drugs in rheumatoid arthritis.

Aarat M Patel1, Daniel Lupash, Douglas Chew, Marc C Levesque, Larry W Moreland.   

Abstract

Entities:  

Year:  2011        PMID： 21755323     DOI： 10.1007/s11926-011-0197-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  3 in total

Review 1.  Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Authors:  Monika Schoels; John Wong; David L Scott; Angela Zink; Pamela Richards; Robert Landewé; Josef S Smolen; Daniel Aletaha
Journal:  Ann Rheum Dis       Date:  2010-05-06       Impact factor: 19.103

2.  Not all "quality-adjusted life years" are equal.

Authors:  C A Marra; S A Marion; D P Guh; M Najafzadeh; F Wolfe; J M Esdaile; A E Clarke; M A Gignac; A H Anis
Journal:  J Clin Epidemiol       Date:  2006-12-22       Impact factor: 6.437

3.  The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study.

Authors:  A Maetzel; L C Li; J Pencharz; G Tomlinson; C Bombardier
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.